{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-25-000024","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.065475+00:00","generated_at":"2026-05-17T15:38:07.406592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assertio Q2 net product sales $28.8M, net loss $16.4M, cash rises to $98.2M","bullets":["GAAP net loss $16.4M ($0.17 per share) vs $3.7M loss ($0.04) in prior year Q2.","Adjusted EBITDA $5.6M, up from $3.1M; adjusted EPS $0.02 vs $0.01.","Rolvedon sales $16.1M (+$1M YoY); Sympazan $3.2M (+$0.5M); Indocin $3.0M (down from $6.9M due to generic competition).","Cash & investments $98.2M, up from $87.3M at Q1 2025; company narrows guidance.","SG&A $17.0M, down from $18.4M, includes $2.4M employee retention tax credit benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-25-000024","json":"https://secwatch.observer/filing/0001808665-25-000024.json","markdown":"https://secwatch.observer/filing/0001808665-25-000024.md","text":"https://secwatch.observer/filing/0001808665-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866525000024/0001808665-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866525000024/asrt-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:38:07.406592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}